|Day Low/High||41.42 / 41.71|
|52 Wk Low/High||30.89 / 57.44|
Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANH, DVN, EXEL, FMC, FSI, GLT, MEOH, MJCO, MOH, NVO, RPXC, TECH, WU, WWE Downgrades: CIGI, IPHI, QUOT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
- New combination treatment option for adults with type 2 diabetes now available in pharmacies
U.S. stock futures decline and European shares trade lower following disappointing earnings from Apple and as Wall Street looks to Wednesday's announcement from the Federal Reserve on interest rates.
Novo Nordisk shares surged to a year-to-date high Wednesday after the world's biggest maker of insulin posted stronger-than-expected first quarter earnings and boosted its full-year outlook.
European stocks drifted lower as investors stepped back from a global market rally after disappointing earnings from Apple and weaker U.S. car sales put investors in a cautious mood.
European stocks slip as Apple earnings take the steam out of the global equity rally.
Postmenopausal women already have a broad menu of locally administered estrogen therapy products to treat vulvar and vaginal atrophy.
New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.
#HemoHero stories to illustrate diverse experiences and inspiring acts of people affected by hemophilia
Attorney Advertising. On March 17, 2017, the nationally recognized class-action law firm of Keller Rohrback L.
Jim Cramer is bullish on Delta, Barracuda Networks, STMicroelectronics, UnitedHealth Group.
This week the markets fell back on earnings -- like Adobe -- and remained afloat, says Jim Cramer.
Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Novo Nordisk A/S (" Novo" or the "Company") (NYSE: NVO).
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
Why the name is sagging, and what it will take to spur the sector higher.
While it's not a surprise that Global Blood is a takeout target, the timing of Novo Nordisk's interest in the company comes as a surprise, according to a stock analyst.
Global Blood Therapeutics is said to have been approached about a merger by Novo Nordisk.